medRxiv preprint doi: https://doi.org/10.1101/2020.11.20.20235754; this version posted November 23, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

1

High infectiousness immediately before COVID-19 symptom onset

2

highlights the importance of contact tracing

3

W.S. Hart1*, P.K. Maini1, R.N. Thompson1,2.

4

Affiliations:

5

1

Mathematical Institute, University of Oxford.

6

2

Christ Church, University of Oxford.

7

*Correspondence to: william.hart@keble.ox.ac.uk.

8
9

Abstract:

10

Understanding changes in infectiousness during COVID-19 infections is critical to assess the

11

effectiveness of public health measures such as contact tracing. Data from known source-

12

recipient pairs can be used to estimate the average infectiousness profile of infected

13

individuals, and to evaluate the proportion of presymptomatic transmissions. Here, we infer

14

the infectiousness profile of COVID-19 infections using a mechanistic approach, and show

15

that this method provides an improved fit to data from source-recipient pairs compared to

16

previous studies. Our results indicate a higher proportion of presymptomatic transmissions

17

than previously thought, with many transmissions occurring shortly before symptom onset.

18

High infectiousness immediately prior to symptom onset highlights the importance of contact

19

tracing, even if contacts from a short time window before symptom onset alone are traced.

20
21
22

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1

medRxiv preprint doi: https://doi.org/10.1101/2020.11.20.20235754; this version posted November 23, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

1

Main text:

2

The precise proportion of SARS-CoV-2 transmissions arising from non-symptomatic (either

3

presymptomatic or asymptomatic) infectors remains uncertain (1, 2). Statistical models can

4

be used to assess the relative contributions of presymptomatic and symptomatic transmission

5

using data from known source-recipient transmission pairs (3â€“6). The distributions of three

6

important epidemiological time periods â€“ the generation time (i.e., the difference between the

7

infection times of the source and recipient) (3, 4, 7, 8), the time from onset of symptoms to

8

transmission (TOST) (4, 9, 10), and the serial interval (i.e., the difference between the

9

symptom onset times of the source and recipient) (4, 11) â€“ can also be inferred. The

10

generation time and TOST distributions also indicate the average infectiousness profile of a

11

host at each time since infection and time since symptom onset, respectively (9, 12). This is

12

important for assessing the effectiveness of public health measures such as contact tracing (3)

13

and for deciding the duration of quarantine/isolation periods (13). Estimates of the generation

14

time distribution of SARS-CoV-2 obtained from transmission pair data have typically

15

involved an assumption that the infectiousness of a host is independent of their symptom

16

status (3, 7, 8, 14, 15). However, such an assumption may both be unjustified (15, 16) and

17

lead to a poor fit to data (4).

18
19

Here, we develop a mechanistic approach for inference from transmission pair data. Our

20

method provides an improved fit to data from SARS-CoV-2 transmission pairs compared to

21

previously used approaches, namely: (i) a model assuming that transmission and symptoms

22

are independent (3, 7, 8, 14), and (ii) a previous statistical method in which this assumption is

23

relaxed (4). We use the fitted models to infer the distributions of epidemiological time

24

intervals and the contribution of presymptomatic infectious individuals to transmission.

25

According to our best-fitting model, we find that the predicted proportion of presymptomatic
2

medRxiv preprint doi: https://doi.org/10.1101/2020.11.20.20235754; this version posted November 23, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

1

transmissions is higher than estimated using standard approaches, with a substantial

2

proportion of transmissions occurring in a short time window prior to symptom onset.

3

Finally, we consider the implications of our results for contact tracing.

4
5

Transmission pair data (Fig. 1A) generally comprise symptom onset dates for known source-

6

recipient pairs. These data may be supplemented with partial information about infection

7

times, consisting of a range of possible exposure dates for the source and/or recipient (3).

8

While the serial interval for each pair can be calculated directly from the data (with some

9

uncertainty, given the unknown precise times of symptom appearance on the onset dates

10

(17)), other time intervals, including the generation time and TOST (which is negative for

11

presymptomatic transmissions), are unobserved. In almost all previous approaches that have

12

been used to estimate the generation time distribution of SARS-CoV-2 from transmission

13

pair data (Fig. 1B, left panel), the infectiousness of the source at a given time since infection

14

is assumed to be independent of their incubation period (3, 7, 8, 14). In contrast, in our

15

mechanistic approach (Fig. 1B, right panel), which is based on compartmental modelling,

16

each infected host passes through three stages of infection â€“ latent (E), presymptomatic

17

infectious (P), and symptomatic infectious (I). Infectiousness is assumed to be constant

18

during each stage but may vary between presymptomatic and symptomatic infectious hosts.

3

medRxiv preprint doi: https://doi.org/10.1101/2020.11.20.20235754; this version posted November 23, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

1
2

Fig. 1. Schematic illustrating time intervals in data from source-recipient pairs and approaches for

3

inference from transmission pair data. A. Important epidemiological time periods in transmission pair data,

4

with time intervals that are not observed directly in grey. B. Assumptions made about the relationship between

5

infectiousness and symptoms within individuals. In standard approaches (left panel), the infectiousness of a host

6

at a given time since infection is independent of their incubation period. In our approach (right panel), we

7

assume that individuals are not infectious during the latent (E) period, and that infectiousness may vary between

8

the presymptomatic infectious (P) and symptomatic infectious (I) periods, for example due to changing

9

behaviour in response to symptoms (18).

10
11

We considered four different models of infectiousness:
4

medRxiv preprint doi: https://doi.org/10.1101/2020.11.20.20235754; this version posted November 23, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

1

1. Our mechanistic approach, with the relative infectiousness levels for presymptomatic

2

(P) and symptomatic (I) infectious hosts estimated from the transmission pair data

3

(the â€œvariable infectiousness modelâ€).

4

2. Our mechanistic approach, with identical infectiousness levels for presymptomatic

5

(P) and symptomatic (I) infectious hosts (the â€œconstant infectiousness modelâ€).

6

3. The best-fitting model from (4) (the â€œFerretti modelâ€).

7

4. The standard approach (3, 8) in which infectiousness is independent of symptom

8
9

status (the â€œindependent transmission and symptoms modelâ€).
Following (4), we fitted each model to data from 191 SARS-CoV-2 transmission pairs

10

obtained by combining five different datasets (3, 9, 19â€“21). To account for uncertainty in the

11

precise times of symptom appearance within the day of onset for the source and recipient

12

(22), we used data augmentation Markov chain Monte Carlo (MCMC). The best fit to the

13

data was obtained using our mechanistic approach in which infectiousness varies between

14

presymptomatic infectious and symptomatic hosts (the variable infectiousness model; Î”AIC

15

= 0). The constant infectiousness model gave the next best fit (Î”AIC = 4.5), followed by the

16

Ferretti model (Î”AIC = 8.3). Finally, the standard assumption of independent transmission

17

and symptoms led to a significantly worse fit compared to the other models (Î”AIC = 44.6).

18
19

For each model, we calculated the predicted distributions of the generation time (Fig. 2A),

20

TOST (Fig. 2B) and serial interval (Fig. 2C) under the set of model parameters that gave the

21

best fit to the data. The empirical serial interval distribution is also plotted in Fig. 2C, for

22

visual confirmation of the goodness of fit of the different models. We found that the

23

variability in the generation time between individuals was lower for the independent

24

transmission and symptoms model compared to the other three models (Fig. 2A). On the

25

other hand, the TOST distribution was most concentrated around the time of symptom onset
5

medRxiv preprint doi: https://doi.org/10.1101/2020.11.20.20235754; this version posted November 23, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

1

for the best-fitting variable infectiousness model, and least concentrated for the independent

2

transmission and symptoms model (Fig. 2B). In our best-fitting model, infectiousness was

3

found to decrease immediately after onset, likely due to behavioural factors that reduce the

4

transmission risk following symptom onset (18).

5
6

Fig. 2. Distributions of epidemiological time intervals estimated by fitting different models to data from

7

191 SARS-CoV-2 transmission pairs. A. Generation time, indicating the relative expected infectiousness of a

8

host at each time since infection. B. Time from onset of symptoms to transmission (TOST), indicating the

9

relative expected infectiousness of a host at each time since symptom onset. C. Serial interval, indicating the

10

periods between sources and recipients developing symptoms. In panel C, the empirical serial interval

11

distribution from the transmission pair data is shown as grey bars. In addition, discretised versions of the serial

12

interval distributions, calculated using the method in (23), are shown in the Supplementary Materials (Fig. S1).

13

In all panels, lines represent: variable infectiousness model (blue), constant infectiousness model (red), Ferretti

14

model (orange), and independent transmission and symptoms model (purple).

15
16

Using the posterior distributions of model parameters that were obtained when we fitted the

17

models to data, we calculated the posterior distribution of the proportion of transmissions

18

occurring prior to symptom onset for each model (Fig. 3A). The median (95% CI)

19

presymptomatic proportion was 0.65 (0.53-0.76), 0.56 (0.50-0.62), 0.55 (0.48-0.62), and 0.49

20

(0.43-0.56) under the variable infectiousness model, constant infectiousness model, Ferretti

6

medRxiv preprint doi: https://doi.org/10.1101/2020.11.20.20235754; this version posted November 23, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

1

model, and independent transmission and symptoms model, respectively. Our central

2

estimate of 65% of transmissions occurring prior to symptom onset using our best-fitting

3

model is higher than estimated in previous studies that have fitted statistical models of

4

infectiousness using transmission pair data (3, 4, 9) â€“ for example, estimates of 37% and 55%

5

were obtained under an assumption of independent transmission and symptoms in (3).

6
7

Fig. 3. The contribution of non-symptomatic infectious individuals to transmission. A. Violin plots

8

indicating posterior distributions for the proportion of transmissions occurring prior to symptom onset for

9

individuals who develop symptoms (i.e., neglecting transmissions from individuals who remain asymptomatic

10

throughout infection) for the different models. B. Posterior distributions of the total proportion of non-

11

symptomatic transmissions, accounting for transmissions from asymptomatic infectious individuals, for the

12

different models. In both panels, violins represent: variable infectiousness model (blue), constant infectiousness

13

model (red), Ferretti model (orange), and independent transmission and symptoms model (purple).

14
15

The estimates in Fig. 3A describe the proportion of transmissions that occur prior to symptom

16

onset, and therefore apply only to individuals who go on to develop symptoms. However,

17

these estimates can be combined with the results of a previous study (1) in which the extent

18

of asymptomatic transmission (i.e., transmissions from individuals who never display

19

symptoms) was characterised (Fig. S2), to obtain estimates for the total proportion of non7

medRxiv preprint doi: https://doi.org/10.1101/2020.11.20.20235754; this version posted November 23, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

1

symptomatic (i.e., either presymptomatic or asymptomatic) transmissions in an entire

2

population of hosts for the different models (Fig. 3B). Again, the non-symptomatic

3

proportion was highest for the variable infectiousness model, and lowest for the independent

4

transmission and symptoms model.

5
6

Finally, we considered the implications of these results for contact tracing (Fig. 4). In Fig.

7

4A, we show the proportion of infectious contacts of hosts who go on to develop symptoms

8

that are identified if contacts are traced up to different times before the symptom onset time

9

of the index case (i.e., for different contact elicitation windows). Long duration contact

10

elicitation windows are impractical and place significant strain on contact tracing systems,

11

leading to contact elicitation windows of two days being used in countries such as the UK

12

(24) and USA (25). In the best-fitting variable infectiousness model, 84% of infectious

13

contacts are estimated to be identified when tracing up to 2 days before symptom onset (Fig.

14

4A, blue dashed). This is due to the clustering of transmission events around the symptom

15

onset time (cf. Fig. 2B) and compares to a lower estimate of only 74% if the standard

16

assumption of independence between transmission and symptoms is made (Fig. 4A, purple).

17

We also explored the effect of the timing of isolation of infected individuals identified

18

through contact tracing, and estimated the reduction in onwards transmissions from infected

19

contacts if contact tracing is conducted quickly (Fig. 4B). Compared to the best-fitting

20

variable infectiousness model, the standard independent transmission and symptoms model

21

estimated a similar reduction in transmission when a host was isolated within 4 days of

22

exposure, but under-predicted the efficacy of isolation later in infection. We assumed that

23

contact identification and isolation is perfectly effective in this analysis, but we also explored

24

the sensitivity of our results to this assumption in the Supplementary Materials. In each case

8

medRxiv preprint doi: https://doi.org/10.1101/2020.11.20.20235754; this version posted November 23, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

1

that we considered, under the best-fitting model a two-day contact elicitation window is more

2

effective than estimated using existing approaches (Fig. S3).

3
4

Fig. 4. Implications for contact tracing. A. Effect of the contact elicitation window: the proportion of

5

infectious contacts found for different times up to which contacts are traced before the symptom onset time of

6

the index case. B. Effect of the timing of isolation: the proportion of onward transmissions prevented through

7

isolation, for different time periods between exposure and isolation. In both panels, lines represent: variable

8

infectiousness model (blue dashed), constant infectiousness model (red), Ferretti model (orange), and

9

independent transmission and symptoms model (purple).

10
11

As we have shown, our mechanistic approach provides an improved fit to transmission pair

12

data, and predicts a higher proportion of transmissions occurring in a short time window

13

before symptom onset, compared to previous approaches. These conclusions are robust to the

14

exact incubation period distribution that we assumed (26) when fitting the different models to

15

transmission pair data (Fig. S4). Our best-fitting model outperforms a model predicated on a

16

critical assumption â€“ that infectiousness is independent of symptom status â€“ which underlies

17

most previous studies in which the generation time distribution of COVID-19 is estimated (3,

18

7, 8, 14). That assumption neglects potential relationships between symptoms and viral
9

medRxiv preprint doi: https://doi.org/10.1101/2020.11.20.20235754; this version posted November 23, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

1

shedding, as well as behavioural changes in response to symptom onset (18). Some

2

alternative assumptions have also been considered when fitting to transmission pair data,

3

such as the possibility that infectiousness depends only on the time since symptom onset,

4

independent of the time of infection (4, 27). If the serial interval is always positive, which is

5

not always the case for COVID-19 (11), this is equivalent to assuming that the serial interval

6

and generation time distributions are identical (15, 23, 28). In a previous study (4), another

7

model (the Ferretti model) was developed in which a hostâ€™s infectiousness could depend on

8

both the time since infection and the time since symptom onset, and was found to outperform

9

models in which their infectiousness depends on either one of these two times alone.

10

However, as we have demonstrated, our mechanistic approach provides an improved fit to

11

data compared to the statistical Ferretti model. In addition, our method has the advantage of

12

being useful for parameterising population-scale compartmental epidemic forecasting

13

models, since the time periods in our approach correspond naturally to compartments (29).

14
15

In summary, using a mechanistic approach to infer key epidemiological quantities from

16

transmission pair data indicates that a higher proportion of SARS-CoV-2 transmissions occur

17

prior to symptoms than previously thought. Furthermore, a significant proportion of

18

transmissions arise shortly before symptom onset, indicating that contact tracing is beneficial

19

even if the contact elicitation window is short. Continued use and refinement of contact

20

tracing programmes in countries worldwide is therefore of clear public health importance.

21

10

medRxiv preprint doi: https://doi.org/10.1101/2020.11.20.20235754; this version posted November 23, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

1

Materials and Methods:

2

Notation and general details

3

Here, we outline the notation used in this section when describing the different models that

4

we considered. For a given transmission pair, we label the source as 1 and the recipient 2, and

5

define:

6

ğ‘¡!" = (time of infection of host ğ‘˜),

7

ğ‘¡#" = (time of symptom onset of host ğ‘˜),

8
9

ğœ!$%," = (incubation period of host ğ‘˜),

ğ‘˜ = 1,2,
ğ‘˜ = 1,2,

ğ‘˜ = 1,2,

ğœ'($ = (generation time),

10

ğ‘¥)*#) = (time from symptom onset of 1 to transmission to 2 (TOST)),

11

ğ‘¥#(+ = (serial interval).

12

Here, ğ‘¡ is used to denote calendar times, ğœ for time intervals relative to the time of infection,

13

and ğ‘¥ for time intervals relative to the time of symptom onset. We denote the probability

14

density functions of the incubation period, generation time, TOST and serial interval as ğ‘“!$% ,

15

ğ‘“'($ , ğ‘“)*#) and ğ‘“#(+ , respectively, and use a capital ğ¹ for the corresponding cumulative

16

distribution functions.

17
18

In addition, we denote the expected infectiousness of a host at time since infection ğœ as ğ›½(ğœ),

19

and the expected infectiousness at time since symptom onset ğ‘¥ as ğ‘(ğ‘¥). Note that

20

ğ›½(ğœ) = ğ‘…, ğ‘“'($ (ğœ),

21

ğ‘(ğ‘¥) = ğ‘…, ğ‘“)*#) (ğ‘¥),

22

where ğ‘…, is the basic reproduction number (for hosts that develop symptoms at some stage

23

during infection). We also let ğ›½(ğœ âˆ£ ğœ!$% ) and ğ‘(ğ‘¥ âˆ£ ğœ!$% ) be the expected infectiousness at

24

time ğœ since infection and at time ğ‘¥ since onset, respectively, conditional on an incubation

11

medRxiv preprint doi: https://doi.org/10.1101/2020.11.20.20235754; this version posted November 23, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

1

period of ğœ!$% (note that ğ›½(ğœ âˆ£ ğœ!$% ) = ğ‘( ğœ âˆ’ ğœ!$% âˆ£ ğœ!$% ) and ğ‘(ğ‘¥ âˆ£ ğœ!$% ) =

2

ğ›½( ğ‘¥ + ğœ!$% âˆ£ ğœ!$% )).

3
4

We considered several different models for infectiousness (details of individual models are

5

given below). In each model, the conditional infectiousness, ğ›½(ğœ âˆ£ ğœ!$% ), or equivalently,

6

ğ‘(ğ‘¥ âˆ£ ğœ!$% ), is specified. The distributions of the generation time and TOST can be recovered

7

from this conditional infectiousness by averaging over the incubation period distribution

8

(which is assumed to be known):
-

9

ğ›½(ğœ) = ğ‘…, ğ‘“'($ (ğœ) = L ğ›½(ğœ âˆ£ ğœ!$% )ğ‘“!$% (ğœ!$% )dğœ!$% ,
,

-

10

ğ‘(ğ‘¥) = ğ‘…, ğ‘“)*#) (ğ‘¥) = L ğ‘(ğ‘¥ âˆ£ ğœ!$% )ğ‘“!$% (ğœ!$% )dğœ!$% .
,

11

Alternative (equivalent) expressions for the generation time and TOST distributions are

12

available for some of the models considered (these are detailed in the â€œModels of

13

infectiousnessâ€ subsection below).

14
15
16

To obtain an expression for the serial interval distribution, we note that
ğ‘¥#(+ = ğ‘¥)*#) + ğœ!$%,. .

17

We assume throughout that ğ‘¥)*#) and ğœ!$%,. are independent, so that the serial interval

18

distribution is given by the convolution
-

19

ğ‘“#(+ (ğ‘¥#(+ ) = L ğ‘“)*#) (ğ‘¥#(+ âˆ’ ğœ!$% )ğ‘“!$% (ğœ!$% )dğœ!$% .
,

20

The proportion of presymptomatic transmissions (out of all transmissions generated by

21

individuals who develop symptoms) can be calculated as
,

22

ğ‘/ = L ğ‘“)*#) (ğ‘¥)*#) )dğ‘¥)*#) ,
0-

23

although simpler equivalent expressions for individual models are also detailed later.
12

medRxiv preprint doi: https://doi.org/10.1101/2020.11.20.20235754; this version posted November 23, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

1
2

Data

3

Following (4), we considered COVID-19 transmission pair data from five different studies

4

(3, 9, 19â€“21), totalling 191 source-recipient pairs. In all 191 transmission pairs, both the

5

source and the recipient developed symptoms, and the symptom onset date of each host was

6

recorded. In four of the five studies (3, 9, 19, 20), intervals of exposure were available for

7

either the source or recipient (or both), whereas in the other (21), only symptom onset dates

8

were recorded.

9
10

Incubation period

11

In the main text, the incubation period was assumed to follow a Gamma distribution with

12

shape parameter 5.807 and scale parameter 0.948 (26). This corresponds to a mean

13

incubation period of 5.5 days and a standard deviation of 2.3 days. However, to demonstrate

14

that our main conclusions are robust to the exact incubation period distribution used, we also

15

repeated our analyses using an alternative, more dispersed, Gamma distributed incubation

16

period with a mean of 5.3 days and a standard deviation of 3.2 days (30) (Fig. S4).

17
18

Models of infectiousness

19

Independent transmission and symptoms model

20

In this model, the infectiousness of each host at a given time since infection is assumed to be

21

independent of their incubation period, so that

22
23
24

ğ›½(ğœ âˆ£ ğœ!$% ) = ğ›½(ğœ) = ğ‘…, ğ‘“'($ (ğœ),
where the generation time distribution, ğ‘“'($ , is prescribed. We assumed (3, 8) that
ğœ'($ âˆ¼ Gamma(ğ‘, ğ‘).

13

medRxiv preprint doi: https://doi.org/10.1101/2020.11.20.20235754; this version posted November 23, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

1

The shape parameter (ğ‘) and scale parameter (ğ‘) were estimated when we fitted the model to

2

transmission pair data.

3
4

The TOST distribution for this model is given by
-

ğ‘“)*#) (ğ‘¥)*#) ) = L ğ‘“'($ (ğ‘¥)*#) + ğœ!$% )ğ‘“!$% (ğœ!$% )dğœ!$% ,

5

,

6

whilst the proportion of presymptomatic transmissions is
-

ğ‘/ = L ğ‘“'($ (ğœ)(1 âˆ’ ğ¹!$% (ğœ))dğœ.

7

,

8

Derivations of these expressions are given in the Supplementary Text.

9
10

Ferretti model

11

Ferretti et al. (4) proposed a model in which the conditional infectiousness was specified as

12

the re-scaled skew-logistic distribution,

13

14
15
16

0(23!"# /5!"# 06)/8
â§ ğ¶ğ‘…, ğ‘’
âª(1 + ğ‘’ 0(23!"# /5!"# 06)/8 )9:; ,
ğ‘( ğ‘¥ âˆ£ ğœ!$% ) =
ğ¶ğ‘…, ğ‘’ 0(206)/8
â¨
,
âª
(1 + ğ‘’ 0(206)/8 )9:;
â©

âˆ’ğœ!$% â‰¤ ğ‘¥ < 0,
ğ‘¥ â‰¥ 0.

Here, ğ‘š!$% is the mean incubation period, ğœ‡, ğœ and ğ›¼ are estimated parameters, and we set
ğ¶=

ğ›¼
ğœ(1 âˆ’ (1 + ğ‘’ (3!"# :6)/8 )09 )

in order to ensure the correct scaling for the infectiousness (see the Supplementary Text).

17
18

The proportion of presymptomatic transmissions is
09

19
20

09

_1 + ğ‘’ 6/8 ` âˆ’ _1 + ğ‘’ (3!"# :6)/8 `
ğ‘/ =
1 âˆ’ (1 + ğ‘’ (3!"# :6)/8 )09

A derivation of this expression is given in the Supplementary Text.

21

14

.

medRxiv preprint doi: https://doi.org/10.1101/2020.11.20.20235754; this version posted November 23, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

1

Our mechanistic model

2

In our mechanistic approach, we divided each infection into three stages: latent (E),

3

presymptomatic infectious (P), and symptomatic infectious (I). The stage durations were

4

assumed to be independent, and infectiousness was assumed to be constant over the duration

5

of each stage. We denote the stage durations by ğ‘¦<///= , their density and cumulative

6

distribution functions by ğ‘“<///= and ğ¹<///= , and the infectiousness of hosts in the P and I

7

stages by ğ›½//= , respectively. We also define the ratio

8

ğ›¼ = ğ›½/ â„ğ›½= .

9

Note that in this model, the basic reproduction number is

10

ğ‘…, = ğ›½/ ğ‘š/ +ğ›½= ğ‘š= ,

11

where ğ‘š//= are the respective mean durations of the P and I stages.

12
13

We further assumed that the durations of each stage followed Gamma distributions, with

14

ğ‘¦< âˆ¼ Gamma cğ‘˜< ,

15

ğ‘¦/ âˆ¼ Gamma cğ‘˜/ ,

16

ğ‘¦= âˆ¼ Gamma cğ‘˜= ,

17
18

1
ğ‘˜!$% ğ›¾
1
ğ‘˜!$% ğ›¾

e,
e,

1
e,
ğ‘˜= ğœ‡

where
ğ‘˜!$% = ğ‘˜< + ğ‘˜/ .

19

In particular, the scale parameters of ğ‘¦< and ğ‘¦/ were both assumed to be equal to 1â„(ğ‘˜!$% ğ›¾),

20

in order to ensure a Gamma distributed incubation period,

21

ğœ!$% = ğ‘¦< + ğ‘¦/ âˆ¼ Gamma cğ‘˜!$% ,

1
ğ‘˜!$% ğ›¾

e.

22

We fixed ğ‘˜!$% = 5.807 and ğ›¾ = 1/(5.807 Ã— 0.948), in order to obtain the specified

23

incubation period distribution (see â€œIncubation periodâ€ subsection above). When we fitted the
15

medRxiv preprint doi: https://doi.org/10.1101/2020.11.20.20235754; this version posted November 23, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

1

model to data, we assumed that ğ‘˜= = 1, so that the symptomatic infectious period followed an

2

exponential distribution. The parameters ğ‘˜< and ğœ‡ were estimated in the fitting procedure.

3

We considered two versions of the model: one in which we assumed ğ›¼ = 1 (the constant

4

infectiousness model), and one in which ğ›¼ was also estimated (the variable infectiousness

5

model).

6
7

For this model, the infectiousness of a host at time ğ‘¥ since symptom onset, conditional on an

8

incubation period of ğœ!$% , can be calculated to be

9

ğ‘( ğ‘¥ âˆ£ ğœ!$% ) = m

ğ›¼ğ¶ğ‘…, (1 âˆ’ ğ¹?()@ (âˆ’ğ‘¥/ğœ!$% ; ğ‘˜/ , ğ‘˜< )),
ğ¶ğ‘…, (1 âˆ’ ğ¹= (ğ‘¥)),

âˆ’ğœ!$% â‰¤ ğ‘¥ < 0,
ğ‘¥ â‰¥ 0,

10

where ğ¹?()@ (ğ‘ ; ğ‘, ğ‘) is the cumulative distribution function of a Beta distributed random

11

variable with parameters ğ‘ and ğ‘, and

12

ğ¶=

13

The TOST distribution is given by
ğ‘“)*#) (ğ‘¥)*#) ) = m

14
15

ğ›½=
ğ‘˜!$% ğ›¾ğœ‡
=
.
ğ‘…, ğ›¼ğ‘˜/ ğœ‡ + ğ‘˜!$% ğ›¾

ğ›¼ğ¶(1 âˆ’ ğ¹/ (âˆ’ğ‘¥)*#) )),
ğ¶(1 âˆ’ ğ¹= (ğ‘¥)*#) )),

ğ‘¥)*#) < 0,
ğ‘¥)*#) â‰¥ 0.

The generation time can be written as
ğœ'($ = ğ‘¦< + ğ‘¦ âˆ— ,

16
17

where ğ‘¦ âˆ— is the time between the start of the P stage and the transmission occurring, and

18

therefore the generation time distribution is given by the convolution

19

ğ‘“'($ _ğœ'($ ` = L

5$%"

,

20
21
22

ğ‘“ âˆ— _ğœ'($ âˆ’ ğ‘¦< `ğ‘“< (ğ‘¦< )dğ‘¦< ,

where the density, ğ‘“ âˆ— , of ğ‘¦ âˆ— satisfies
ğ‘“

âˆ— (ğ‘¦ âˆ— )

= ğ¶ pğ›¼_1 âˆ’ ğ¹/

(ğ‘¦ âˆ— )`

Bâˆ—

+ L _1 âˆ’ ğ¹= (ğ‘¦ âˆ— âˆ’ ğ‘¦/ )`ğ‘“/ (ğ‘¦/ )dğ‘¦/ q.
,

The proportion of presymptomatic transmissions is

16

medRxiv preprint doi: https://doi.org/10.1101/2020.11.20.20235754; this version posted November 23, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

ğ›½/ ğ‘š/
ğ›¼ğ‘˜/ ğœ‡
=
.
ğ‘…,
ğ›¼ğ‘˜/ ğœ‡ + ğ‘˜!$% ğ›¾

1

ğ‘/ =

2

Derivations of these formulae are given in the Supplementary Text.

3
4

Likelihood and model fitting

5

For a single transmission pair (labelled ğ‘›), suppose that the times of infection for the source

6

and recipient are known to lie in the intervals [ğ‘¡!;,C , ğ‘¡!;,D ] and [ğ‘¡!.,C , ğ‘¡!.,D ], respectively (where

7

these intervals may be infinite), and that their symptom onset times, ğ‘¡#; and ğ‘¡#. , are known

8

exactly. In this case, the likelihood of the parameters, ğœƒ, of the model of infectiousness under

9

consideration (when only that transmission pair is observed) is given by
)!+,) )!',)

10

ğ¿($) (ğœƒ) =

1
L
ğ‘…,

L ğ‘(ğ‘¡!. âˆ’ ğ‘¡#; âˆ£ ğ‘¡#; âˆ’ ğ‘¡!; , ğœƒ) ğ‘“!$% (ğ‘¡#; âˆ’ ğ‘¡!; )ğ‘“!$% (ğ‘¡#. âˆ’ ğ‘¡!. )dğ‘¡!; dğ‘¡!. ,

)!+,* )!',*

11

where the dependence of the conditional expected infectiousness, ğ‘(ğ‘¥ âˆ£ ğœ!$% , ğœƒ), on the model

12

parameters, ğœƒ, is indicated explicitly. A derivation of this expression is given in the

13

Supplementary Text. Assuming that each transmission pair in our dataset was independent,

14

the overall likelihood was therefore given by the product of the contributions, ğ¿($) (ğœƒ), from

15

each individual transmission pair, i.e.,
E

16

ğ¿(ğœƒ) = w ğ¿($) (ğœƒ),
$F;

17

where ğ‘ is the total number of transmission pairs.

18
19

In order to account for uncertainty in the exact symptom onset times within the day of onset,

20

we fitted the models to the data using data augmentation MCMC. In particular, in alternating

21

steps of the chain, we updated either the vector of model parameters, ğœƒ, or the symptom onset

22

times of each source and recipient. The chain was run for 2.5 million steps, of which the first

17

medRxiv preprint doi: https://doi.org/10.1101/2020.11.20.20235754; this version posted November 23, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

1

500,000 were discarded as burn-in. Posterior distributions of parameters were obtained by

2

recording only every 100 iterations of the chain (assuming a uniform prior distribution for

3

each model parameter), whilst the parameter values that maximised the likelihood were taken

4

as point estimates. Full details of the model fitting procedure are given in the Supplementary

5

Text.

6
7

Distributions of the presymptomatic and total non-symptomatic proportion of transmissions

8

Expressions for the proportion of transmissions, ğ‘/ , generated prior to symptom onset, are

9

given for the individual models above. Once asymptomatic cases are accounted for, the

10

overall non-symptomatic proportion of transmissions can be written as
ğ‘G ğ‘ŸG + (1 âˆ’ ğ‘G )ğ‘/
,
ğ‘G ğ‘ŸG + (1 âˆ’ ğ‘G )

11
12

where ğ‘G is the proportion of infected individuals who remain asymptomatic, and ğ‘ŸG is the

13

ratio between the average number of secondary cases generated by an asymptomatic host and

14

the number generated by a host who at some point develops symptoms. A derivation of this

15

expression is given in the Supplementary Text.

16
17

For each model, we used the posterior parameter distributions that were obtained when we

18

fitted the model to data to obtain a sample from the posterior distribution of ğ‘/ . In order to

19

estimate the total proportion of non-symptomatic transmissions, we assumed the distributions

20

ğ‘G âˆ¼ Beta(85,186),

21

ğ‘ŸG âˆ¼ Lognormal(âˆ’1.04, 0.65. ),

22

which are consistent with estimates in (1). These distributions are shown in Fig. S2. We then

23

combined samples from the assumed distributions of ğ‘G and ğ‘ŸG with the sample that we

24

generated from the posterior distribution of ğ‘/ to obtain a distribution for the total proportion

25

of non-symptomatic transmissions.
18

medRxiv preprint doi: https://doi.org/10.1101/2020.11.20.20235754; this version posted November 23, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

1
2

Contact tracing

3

First, we considered the proportion of the infectious contacts of a symptomatic index case

4

that will be found, if contacts are traced up to ğ‘‘; days before the time of symptom onset (of

5

the index host). In this case, assuming that it is possible to trace a fraction ğœ€; of the hostâ€™s

6

total contacts between times âˆ’ğ‘‘; and âˆ since symptom onset, then the proportion of

7

infectious contacts found is equal to
ğœ€; (1 âˆ’ ğ¹)*#) (âˆ’ğ‘‘; )).

8
9
10

Note that we assumed that the TOST distribution for a detected index case does not differ
from that of a random infected individual.

11
12

We then considered the proportion of transmissions that can be prevented, if an infected

13

individual (identified through contact tracing) is isolated ğ‘‘. days after exposure. Assuming

14

that a proportion ğœ€. of infectious contacts that would otherwise occur are prevented during

15

the isolation period, the overall proportion of onward infections prevented through isolation

16

is

17

ğœ€. _1 âˆ’ ğ¹'($ (ğ‘‘. )`.

18
19

In the main text, we assumed that ğœ€; = ğœ€. = 1 (i.e., contact identification and isolation are

20

both 100% effective), although values of ğœ€; and ğœ€. below 1 are considered in the

21

Supplementary Materials (Fig. S3).

22

19

medRxiv preprint doi: https://doi.org/10.1101/2020.11.20.20235754; this version posted November 23, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

1

References:

2

1.

D. Buitrago-Garcia, D. Egli-Gany, M. J. Counotte, S. Hossmann, H. Imeri, A. M.

3

Ipekci, G. Salanti, N. Low, Occurrence and transmission potential of asymptomatic

4

and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-

5

analysis. PLoS Med. 17, e1003346 (2020).

6

2.

M. Casey, J. Griffin, C. G. McAloon, A. W. Byrne, J. M. Madden, D. McEvoy, A. B.

7

Collins, K. Hunt, A. Barber, F. Butler, E. A. Lane, K. O. Brien, P. Wall, K. A. Walsh,

8

S. J. More, Pre-symptomatic transmission of SARS-CoV-2 infection: a secondary

9

analysis using published data. medRxiv (2020), doi:10.1101/2020.05.08.20094870.

10

3.

L. Ferretti, C. Wymant, M. Kendall, L. Zhao, A. Nurtay, L. Abeler-DÃ¶rner, M. Parker,

11

D. Bonsall, C. Fraser, Quantifying SARS-CoV-2 transmission suggests epidemic

12

control with digital contact tracing. Science. 368, eabb6936 (2020).

13

4.

L. Ferretti, A. Ledda, C. Wymant, L. Zhao, V. Ledda, L. Abeler-DÃ¶rner, M. Kendall,

14

A. Nurtay, H.-Y. Cheng, T.-C. Ng, H.-H. Lin, R. Hinch, J. Masel, A. M. Kilpatrick, C.

15

Fraser, The timing of COVID-19 transmission. medRxiv (2020),

16

doi:10.1101/2020.09.04.20188516.

17

5.

18
19

W. Zhang, Estimating the presymptomatic transmission of COVID19 using incubation
period and serial interval data. medRxiv (2020), doi:10.1101/2020.04.02.20051318.

6.

Y. Liu, Centre for Mathematical Modelling of Infectious Diseases nCoV Working

20

Group, S. Funk, S. Flasche, The contribution of pre-symptomatic infection to the

21

transmission dynamics of COVID-2019. Wellcome Open Res. 5, 58 (2020).

22

7.

Y. Deng, C. You, Y. Liu, J. Qin, X. H. Zhou, Estimation of incubation period and

23

generation time based on observed length-biased epidemic cohort with censoring for

24

COVID-19 outbreak in China. Biometrics, 1â€“13 (2020).
20

medRxiv preprint doi: https://doi.org/10.1101/2020.11.20.20235754; this version posted November 23, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

1

8.

T. Ganyani, C. Kremer, D. Chen, A. Torneri, C. Faes, J. Wallinga, N. Hens,

2

Estimating the generation interval for coronavirus disease (COVID-19) based on

3

symptom onset data, March 2020. Eurosurveillance. 25, 2000257 (2020).

4

9.

X. He, E. H. Y. Lau, P. Wu, X. Deng, J. Wang, X. Hao, Y. C. Lau, J. Y. Wong, Y.

5

Guan, X. Tan, X. Mo, Y. Chen, B. Liao, W. Chen, F. Hu, Q. Zhang, M. Zhong, Y. Wu,

6

L. Zhao, F. Zhang, B. J. Cowling, F. Li, G. M. Leung, Temporal dynamics in viral

7

shedding and transmissibility of COVID-19. Nat. Med. 26, 672â€“675 (2020).

8

10.

9

Bonhoeffer, COVID-19 infectivity profile correction. Swiss Med. Wkly. 150, w20336

10
11

P. Ashcroft, J. S. Huisman, S. Lehtinen, J. A. Bouman, C. L. Althaus, R. R. Regoes, S.

(2020).
11.

Z. Du, X. Xu, Y. Wu, L. Wang, B. J. Cowling, L. A. Meyers, Serial interval of

12

COVID-19 among publicly reported confirmed cases. Emerg. Infect. Dis. 26, 1341â€“

13

1343 (2020).

14

12.

15
16

epidemic. PLoS One. 2, e758 (2007).
13.

17
18

C. Fraser, Estimating individual and household reproduction numbers in an emerging

P. Ashcroft, S. Lehtinen, S. Bonhoeffer, Quantifying the impact of quarantine duration
on COVID-19 transmission. medRxiv (2020), doi:10.1101/2020.09.24.20201061.

14.

J. Knight, S. Mishra, Estimating effective reproduction number using generation time

19

versus serial interval, with application to covid-19 in the Greater Toronto Area,

20

Canada. Infect. Dis. Model. 5, 889â€“896 (2020).

21

15.

S. Lehtinen, P. Ashcroft, S. Bonhoeffer, On the relationship between serial interval,

22

infectiousness profile and generation time. medRxiv (2020),

23

doi:10.1101/2020.09.18.20197210.

24

16.

S. Bacallado, Q. Zhao, N. Ju, Letter to the editor: Generation interval for COVID-19
21

medRxiv preprint doi: https://doi.org/10.1101/2020.11.20.20235754; this version posted November 23, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

1
2

based on symptom onset data. Eurosurveillance. 25, 2001381 (2020).
17.

R. N. Thompson, J. E. Stockwin, R. D. van Gaalen, J. A. Polonsky, Z. N. Kamvar, P.

3

A. Demarsh, E. Dahlqwist, S. Li, E. Miguel, T. Jombart, J. Lessler, S. Cauchemez, A.

4

Cori, Improved inference of time-varying reproduction numbers during infectious

5

disease outbreaks. Epidemics. 29, 100356 (2019).

6

18.

7
8

P. Manfredi, A. Dâ€™Onofrio, Eds., Modeling the interplay between human behavior and
the spread of infectious diseases (Springer, New York, 2013).

19.

9

W. Xia, J. Liao, C. Li, Y. Li, X. Qian, X. Sun, H. Xu, G. Mahai, X. Zhao, L. Shi, J.
Liu, L. Yu, M. Wang, Q. Wang, A. Namat, Y. Li, J. Qu, Q. Liu, X. Lin, S. Cao, S.

10

Huan, J. Xiao, F. Ruan, H. Wang, Q. Xu, X. Ding, X. Fang, F. Qiu, J. Ma, Y. Zhang,

11

A. Wang, Y. Xing, S. Xu, Transmission of corona virus disease 2019 during the

12

incubation period may lead to a quarantine loophole. medRxiv (2020),

13

doi:10.1101/2020.03.06.20031955.

14

20.

H. Y. Cheng, S. W. Jian, D. P. Liu, T. C. Ng, W. T. Huang, H. H. Lin, Contact Tracing

15

Assessment of COVID-19 Transmission Dynamics in Taiwan and Risk at Different

16

Exposure Periods before and after Symptom Onset. JAMA Intern. Med. 180, 1156â€“

17

1163 (2020).

18

21.

J. Zhang, M. Litvinova, W. Wang, Y. Wang, X. Deng, X. Chen, M. Li, W. Zheng, L.

19

Yi, X. Chen, Q. Wu, Y. Liang, X. Wang, J. Yang, K. Sun, I. M. Longini, M. E.

20

Halloran, P. Wu, B. J. Cowling, S. Merler, C. Viboud, A. Vespignani, M. Ajelli, H.

21

Yu, Evolving epidemiology and transmission dynamics of coronavirus disease 2019

22

outside Hubei province, China: a descriptive and modelling study. Lancet Infect. Dis.

23

20, 793â€“802 (2020).

24

22.

R. N. Thompson, Novel coronavirus outbreak in Wuhan, China, 2020: intense

22

medRxiv preprint doi: https://doi.org/10.1101/2020.11.20.20235754; this version posted November 23, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

1

surveillance is vital for preventing sustained transmission in new locations. J. Clin.

2

Med. 9, 498 (2020).

3

23.

A. Cori, N. M. Ferguson, C. Fraser, S. Cauchemez, A new framework and software to

4

estimate time-varying reproduction numbers during epidemics. Am. J. Epidemiol. 178,

5

1505â€“1512 (2013).

6

24.

7
8

and-trace-how-it-works).
25.

9
10

NHS test and trace: how it works, (available at https://www.gov.uk/guidance/nhs-test-

Investigating a COVID-19 Case, (available at https://www.cdc.gov/coronavirus/2019ncov/php/contact-tracing/contact-tracing-plan/investigating-covid-19-case.html).

26.

S. A. Lauer, K. H. Grantz, Q. Bi, F. K. Jones, Q. Zheng, H. R. Meredith, A. S. Azman,

11

N. G. Reich, J. Lessler, The incubation period of coronavirus disease 2019 (CoVID-

12

19) from publicly reported confirmed cases: estimation and application. Ann. Intern.

13

Med. 172, 577â€“582 (2020).

14

27.

E. L. Davis, T. C. D. Lucas, A. Borlase, T. M. Pollington, S. Abbott, D. Ayabina, T.

15

Crellen, J. Hellewell, L. Pi, G. F. Medley, T. D. Hollingsworth, P. Klepac, An

16

imperfect tool: COVID-19 â€œtest & traceâ€ success relies on minimising the impact of

17

false negatives and continuation of physical distancing. medRxiv (2020),

18

doi:10.1101/2020.06.09.20124008.

19

28.

20
21

T. Britton, G. S. Tomba, Estimation in emerging epidemics: Biases and remedies. J. R.
Soc. Interface. 16, 20180670 (2019).

29.

W. S. Hart, P. K. Maini, C. A. Yates, R. N. Thompson, A theoretical framework for

22

transitioning from patient-level to population-scale epidemiological dynamics:

23

influenza A as a case study. J. R. Soc. Interface. 17, 20200230 (2020).

24

30.

N. Linton, T. Kobayashi, Y. Yang, K. Hayashi, A. Akhmetzhanov, S. Jung, B. Yuan,
23

medRxiv preprint doi: https://doi.org/10.1101/2020.11.20.20235754; this version posted November 23, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

1

R. Kinoshita, H. Nishiura, Incubation period and other epidemiological characteristics

2

of 2019 novel coronavirus infections with right truncation: a statistical analysis of

3

publicly available case data. J. Clin. Med. 9, 538 (2020).

4
5

Acknowledgments: Thanks to members of the Wolfson Centre for Mathematical Biology at

6

the University of Oxford for useful discussions about this work.

7

Funding: WSH was funded by an EPSRC Excellence Award for his doctoral studies. RNT

8

was funded by a Junior Research Fellowship from Christ Church, Oxford. The funders had

9

no role in study design, data collection and analysis, decision to publish, or preparation of the

10

manuscript.

11

Author contributions: RNT and WSH conceived the research; All authors designed the

12

study; WSH carried out the research; WSH drafted the manuscript; RNT and PKM

13

supervised the research; All authors revised the manuscript and gave final approval for

14

publication.

15

Competing interests: Authors declare no competing interests.

16

Data and materials availability: The transmission pair data used in our analyses are

17

available in the Supplementary Materials. Code for reproducing our results is available at

18

https://github.com/will-s-hart/COVID-19-Infectiousness-Profile.

24

